Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36.

Article  CAS  PubMed  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942–50.

Article  CAS  PubMed  Google Scholar 

Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5.

Article  PubMed  PubMed Central  Google Scholar 

de Lusignan S, Crawford L, Munro N. Creating and using real-world evidence to answer questions about clinical effectiveness. J Innov Health Inform. 2015;22(3):368–73.

Article  PubMed  Google Scholar 

Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: The ISPOR real-world data task force report. Value Health. 2007;10(5):326–35.

Article  PubMed  Google Scholar 

Rugo HS, Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Cristofanilli M, Torres MA, Curigliano G, et al. Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. NPJ Breast Cancer. 2022;8(1):114.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marmé F, Brucker C, Decker T, Fasching P, Göhler T, Jackisch C, Janssen J, Koehler A, Luedtke-Heckenkamp K, Lüftner D, et al. 411P Therapy management and safety of 1st-line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine: real-world data from the RIBANNA study (5th interim analysis (IA)). Ann Oncol. 2023;34:S355–6.

Article  Google Scholar 

Laurentiis MD, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, Dent SF, Martin M, Ring AE, Cottu PH, et al. Updated results from the phase IIIb complement-1 study of ribociclib (RIB) plus letrozole (LET) in the treatment of HR+, HER2-advanced breast cancer (ABC). J Clin Oncol. 2020;38(15_suppl):1055–1055.

Article  Google Scholar 

Low JL, Lim E, Bharwani L, Wong A, Wong K, Ow S, Lim SE, Lee M, Choo J, Lim J, et al. Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia. Ther Adv Med Oncol. 2022;14:17588359221139678.

Article  CAS  PubMed  PubMed Central  Google Scholar 

National Comprehensive Cancer Network. Breast Cancer (Version 2.2024) https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed April 4, 2024.

Gennari A, Andre F, Barrios CH, Cortes J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–95.

Article  CAS  PubMed  Google Scholar 

Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, Denkert C, Poortmans P, Weber WP, Thurlimann B, et al. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the primary therapy of individuals with early breast cancer 2023. Ann Oncol. 2023;34(11):970–86.

Article  CAS  PubMed  Google Scholar 

Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol. 2011;29(32):4273–8.

Article  PubMed  Google Scholar 

Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90–2.

Article  CAS  PubMed  Google Scholar 

Cardoso F, Costa A, Senkus E, Aapro M, Andre F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol. 2017;28(12):3111.

Article  CAS  PubMed  PubMed Central  Google Scholar 

R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria 2023.

Yousuf M, Alam M, Shamsi A, Khan P, Hasan GM, Rizwanul Haque QM, Hassan MI. Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: a review on therapeutic implications. Int J Biol Macromol. 2022;218:394–408.

Article  CAS  PubMed  Google Scholar 

Ammazzalorso A, Agamennone M, De Filippis B, Fantacuzzi M. Development of CDK4/6 inhibitors: a five years update. Molecules. 2021;26(5):1488. https://doi.org/10.3390/molecules26051488

Article  CAS  PubMed  PubMed Central  Google Scholar 

Im S-A, Lu Y-S, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee K-S, Campos-Gomez S, et al. Overall survival with Ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307–16.

Article  CAS  PubMed  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andre F, Winer EP, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48.

Article  CAS  PubMed  Google Scholar 

De Laurentiis M, Borstnar S, Campone M, Warner E, Bofill JS, Jacot W, Dent S, Martin M, Ring A, Cottu P, et al. Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. Breast Cancer Res Treat. 2021;189(3):689–99.

Article  PubMed  PubMed Central  Google Scholar 

Torregrosa-Maicas MD, Del Barco-Berrón S, Cotes-Sanchís A, Lema-Roso L, Servitja-Tormo S, Gironés-Sarrió R. Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer. Clin Transl Oncol. 2022;24(6):1033–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Finn RS, Rugo HS, Dieras VC, Harbeck N, Im S-A, Gelmon KA, Walshe JM, Martin M, Gregor MCM, Bananis E, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. J Clin Oncol. 2022;40(17_suppl):LBA1003.

Article  Google Scholar 

Llombart-Cussac A, Pérez-García JM, Ezquerra MB-, Dalenc F, Gil-Gil M, Ruíz-Borrego M, Gavilá J, Schmid P, Zamora P, Wheatley D, et al. Abstract RF01–03: PARSIFAL-LONG: extended follow-up of hormone receptor-positive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study. Cancer Res. 2024;84(9_Supplement):RF01-03.

Article  Google Scholar 

Rugo HS, Liu X, Li B, McRoy L, Chen C, Layman RM, Brufsky A. Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron database. Int J Cancer. 2024;154(4):701–11.

Article  CAS  PubMed  Google Scholar 

Buller W, Pallan L, Chu T, Khoja L. CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset. J Oncol Pharm Pract. 2023;29(8):1825–35.

Article  CAS  PubMed  Google Scholar 

Muller C, Kiver V, Solomayer EF, Wagenpfeil G, Neeb C, Blohmer JU, Abramian AV, Maass N, Schutz F, Kolberg-Liedtke C, et al. CDK4/6 inhibitors in advanced HR+/HER2 - breast cancer: a multicenter real-world data analysis. Breast Care (Basel). 2023;18(1):31–41.

Article  PubMed  Google Scholar 

Olsson LT, Walens A, Hamilton AM, Benefield HC, Fleming JM, Carey LA, Hursting SD, Williams KP, Troester MA. Obesity and breast cancer metastasis across genomic subtypes. Cancer Epidemiol Biomark Prev. 2022;31(10):1944–51.

Article  Google Scholar 

Lee K, Kruper L, Dieli-Conwright CM, Mortimer JE. The impact of obesity on breast cancer diagnosis and treatment. Curr Oncol Rep. 2019;21(5):41.

Article  PubMed  PubMed Central  Google Scholar 

Saleh K, Carton M, Dieras V, Heudel PE, Brain E, D’Hondt V, Mailliez A, Patsouris A, Mouret-Reynier MA, Goncalves A, et al. Impact of body mass index on overall survival in patients with metastatic breast cancer. Breast. 2021;55:16–24.

Article  PubMed  Google Scholar 

Franzoi MA, Eiger D, Ameye L, Ponde N, Caparica R, De Angelis C, Brandao M, Desmedt C, Di Cosimo S, Kotecki N, et al. Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy. J Natl Cancer Inst. 2021;113(4):462–70.